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Abstract 
Background: Weight gain is one of the consequences of estrogen deficiency and constitutes a 
major health problem. The present study highlights the effects of N-methyl pyrrolidone 
(NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized 
rat model. Results: Ovariectomy resulted in body weight gain, increased femoral marrow 
adipocytes, and hypertrophic adipocytes in white adipose tissue, distorted serum leptin, TNF-
α and PPARγ levels. Treatment with NMP normalized these parameters similar to the control 
group. In vitro, NMP inhibited the differentiation of 3T3-L1 preadipocytes and hMSCs, 
indicating its antiadipogenic effect. Moreover, PPARγ was significantly reduced with NMP 
treatment in in vivo and in vitro experiments. NMP inhibited BRD2 and BRD4 binding in an 
AlphaScreen assay, with an IC50 of 3mM and 4mM, respectively. The effect of NMP was 
consistent with its role as a bromodomain inhibitor. 
Conclusion: Our data indicates that NMP inhibits the adipogenic effect of estrogen 
deficiency at the level of PPARγ expression by BRD4 inhibition.   
 
Keywords: osteoporosis, adipocytes, epigenetic modulator, small inhibitor molecule                                                                                                                                                          
  
3 
 
Background 
 Osteoporosis is the most common metabolic bone disease which is aggravated by 
estrogen deficiency. It’s manifested as a systemic impairment of mass, strength and micro-
architecture of bone, which increases the predisposition to fractures as a result of bone fragility 
[1]. Additionally, estrogen deficiency is also associated with an increased risk of other 
metabolic diseases including obesity, heart disease, diabetes, and hypertension [2]. Estrogen 
levels in the body are very important since they regulate key features of metabolism such as 
food intake, body weight, glucose homeostasis/insulin, body fat distribution, 
lipolysis/lipogenesis, inflammation, reproduction, and cognition [3]. The increase in 
bodyweight/obesity in menopausal women accompanied with postmenopausal osteoporosis is 
a significant public health concern [4]. 
 It is known that an inverse relationship exists between osteogenic and adipogenic 
programming. Multiple signaling pathways have been demonstrated to preferentially induce 
osteogenesis at the expense of adipogenesis, or vice versa. The ability of mesenchymal stem 
cells (MSCs) to differentiate in one or more of five mesenchymal lineages is determined by 
different factors such as; hormones, cytokines, and growth factors [5]. There is a known but not 
a well-defined relationship between bone mass, bone strength and bone marrow fat content. In 
normal state the bone marrow balance of osteoblastic and adipocyte cell differentiation favors 
bone formation, while during osteoporosis there is an increase in adipocyte formation [6]. Bone 
marrow adipose tissue is inversely associated with bone mineral density (BMD) in 
postmenopausal osteoporosis and other conditions such as old age and treatment with 
glucocorticoids medications [7, 8]. Data also suggests that estrogen plays an important role not 
only in the homeostasis of bone marrow fat but also in regulating body fat distribution in 
women. It has been shown that postmenopausal woman have higher total and abdominal fat 
mass [9] and lower lean body mass than premenopausal women [10]. Estrogen deficiency 
among menopaused elderly women leads to the development of visceral fat depots which are 
known to be associated with other severe diseases including diabetes mellitus type 2, the 
metabolic syndrome, and cardiovascular diseases, while bone is resorbed [11-14].  
On the molecular level, peroxisome proliferator-activated receptors γ (PPARγ) is considered 
the master regulator of adipogenesis and without it, the precursor cells are incapable of 
expressing any known aspect of adipocyte phenotype [15].  
Epigenetic regulation is a known fundamental regulatory mechanism for normal 
development which causes heritable differences in cell behaviors [16]. Epigenetic therapy is of 
particular interest as a pluripotent approach to directly target different medical conditions. 
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Bromo and extra terminal (BET)-protein bromodomain inhibitors are a novel epigenetic 
approach to treat a wide range of diseases. Bromodomains are protein motifs binding acetyl-
lysine residues of nucleosomal histones or other proteins [17]. BET-proteins contain 2 
bromodomain domains and an extraterminal domain [18]. They serve as scaffolding modules 
that recruit transcription regulatory factors to chromatin to form protein complexes which 
regulate gene transcription in response to signal transduction. BRD2 and BRD4, both members 
of the BET-protein family were recently shown to play a critical role in adipogenesis [19-21].  
 In the last years, we showed that N-methyl pyrrolidone (NMP), a small molecule used 
as a drug solvent and as a constituent in FDA-approved medical devices targets osteoblast and 
osteoclast differentiation [22, 23]. Indeed, NMP has demonstrated to have polyvalent 
capabilities; it enhances BMP-2-induced osteoblast differentiation and bone regeneration and 
disturbs osteoclast differentiation and bone resorption [22, 23]. Recently, in an animal model 
of osteoporosis we showed that NMP exhibits an anti-osteoporotic capability [24] while in an 
in vitro inflammation model NMP attenuated the production of LPS induced pro-inflammatory 
cytokines [25]. 
 Osteoblasts and adipocytes differentiate from a common precursor, bone marrow 
mesenchymal stem cells (BMSCs) [26, 27]. There is an estrogen- linked reduction in 
osteogenesis that is accompanied by an increase in adipogenesis. This switch increases white 
adipocytes and decreases osteoblasts numbers, triggering estrogen deficiency-related bone loss 
[28]. The goal of this study was to determine the effect of NMP on adipogenesis in vitro and 
white fat tissue accumulation and marrow fat content in an in vivo model of estrogen deficiency-
induced osteoporosis.  
 
 
Results  
Potency of NMP treatment on weight gain, bone marrow adiposity and biomarkers  
 Ovariectomy significantly increased the body mass of animals, especially in the first 
three weeks after surgery (first 20 days of the study). OVX animals weighted ~50 g more than 
their Sham counterparts and only ~30 g more than the OVX NMP group, during these first 3 
weeks (Fig.1A). Over time the body weight gain increased steadily but was less striking, 
although a difference of ~70 g was visible between Sham Veh and OVX Veh groups by the end 
of the study, which equals a 20% weight increase. While throughout the duration of the 
treatment, NMP treated animals gained significantly less weight than the OVX animals (~40g). 
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 It is known that weight gain after menopause is often due to the decline of estrogen 
levels. For this reason, we not only measured the body mass of the animals during this treatment 
but the levels of different biomarkers involved in weight regulation such as estrogen, TNF-α 
and leptin were also measured (Fig.1C). Estradiol level in the OVX Veh group was significantly 
lower than in Sham Veh group. Even though there was an increase in estradiol level in OVX 
NMP group, no statistically significant difference was observed between OVX Veh and OVX 
NMP groups. The serum TNF-α level was significantly more elevated in OVX Veh than in 
Sham Veh and NMP OVX animals. The same trend was observed for the serum leptin level 
(Fig.1C).  
The three common findings in osteoporotic bone are: increased levels of osteoclastogenesis, 
decreased osteoblastogenesis and increased bone marrow adipogenesis. The first is associated 
with a lack of estrogens and therefore is more commonly seen in women during their 
postmenopausal years. The reduction in osteoblastogenesis, with the concomitant increase in 
adipogenesis, is the consequence of the shift in the differentiation of bone marrow cells 
predominantly into adipocytes [6]. The consequence of these changes is a progressively fatty 
bone with reduced bone mass. As shown in the figure 1B estrogen deficiency increases fat 
accumulation in bone marrow. The NMP treatment of ovariectomized animal counteracts this 
process. 
 
Histology of white adipose tissue (WAT) and mRNA PPARγ levels 
 Ovariectomy also resulted in increased size of adipocytes (hypertrophy) from white 
adipose tissues (Fig. 2A). As seen from the supplementary data NMP treatment (OVX NMP) 
led to a reduction of visceral white fat pads. Ovariectomized rats (OVX Veh) showed a 
significant decrease in the number of adipose cells per area. Similarly, adipocytes from OVX 
Veh rats had a larger mean cell circumference and area than the adipocytes from the Sham Veh 
and OVX NMP group (Fig.2B)  
 To determine whether the effects of NMP on WAT adipocyte size are associated with 
changes in PPARγ, we measured mRNA levels of PPARγ in WAT from the animal groups. In 
the OVX Veh group, PPARγ levels were substantially upregulated. Administration of NMP on 
the ovariectomized animals significantly decreased PPARγ expression.  
 
 
 
NMP inhibits adipocyte formation from hMSCs 
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Mesenchymal stem cells (MSCs) can differentiate into several lineages, including 
adipocytes [26, 27]. To induce adipogenic differentiation, sub-confluent (70%) human 
mesenchymal stem cells (hMSCs) were seeded in 12 well plates, cultured and treated for 14 
days in adipogenic medium (MDI). hMSCs were induced to differentiate into mature adipocytes 
and lipid accumulation were assessed by Oil-red O staining (Fig. 3B). Lipid accumulation in 
MDI-treated group was evident compared to the control group. Cells co-treated with MDI and 
with 5 mM NMP or 10 mM NMP shows less lipid accumulation than the MDI-induced cells. 
This anti-adipogenic effect of NMP was also observed when the absorbance of the Oil-red O 
staining was measured (Fig.3A) displaying a significant difference between MDI-induced and 
MDI/NMP treated cells. Consistently, expression level of PPARγ, a crucial adipogenic marker 
which plays a central role in adipocyte gene expression and differentiation, was also 
significantly reduced upon NMP treatment (Fig. 3C). 
 
NMP inhibits adipocyte maturation 
 To study the effect of NMP on the differentiation of pre-adipocytes to mature 
adipocytes, we employed 3T3-L1 cells. These cells are a well-established pre-adipocyte cell 
line used for the investigation of preadipocytes conversion into adipocytes. Post-confluent 
3T3-L1 preadipocytes were treated with adipogenic medium (MDI) then treated with different 
doses of NMP (5 and 10 mM) or without NMP for 10 days.  To determine the effect of NMP 
on adipogenic differentiation the accumulated intracellular lipid was stained with Oil-Red O 
dye and quantified. Oil Red O staining performed on day 10 of the treatment shown in Fig.4B 
suggests that 3T3-L1 preadipocytes differentiate into mature adipocytes. However, cells co-
treated with 5 mM NMP for 10 days showed inhibition of MDI-induced lipid droplet 
accumulation, and 10 mM NMP nearly fully blocked lipid droplet accumulation.  As shown in 
Fig.4A, a dose-dependent reduction in lipid accumulation was observed in the cells treated 
with NMP, suggesting that NMP inhibits adipocyte transcription factors during adipocyte 
differentiation. To further evaluate the effect of NMP on adipocyte formation, the expression 
level of PPARγ was investigated. The mRNA levels of PPARγ were significantly lower in 10 
mM NMP-treated 3T3-L1 pre-adipocytes compared to 5 mM NMP or MDI alone treated cells 
(Fig.4C). 
 
Effect of NMP on the binding ability of BET bromodomains 
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 To assess the possibility of NMP acting as a bromodomain inhibitor particularly for 
BRD2 and BRD4, both associated with adipogenesis, we used an AlphaScreen assay format to 
determine the effect of NMP on recombinant human BET bromodomains. Our results suggest 
that NMP inhibits the binding of acetyl-lysines to BRD2-BD1BD2, a member of the ‘BET’ 
subfamily of bromodomain-containing proteins [29]. AlphaScreen dose response experiments 
performed against BRD2 and BRD4 as a whole and BRD2 BD1 and BRD2 BD2 component 
independently gave raise to millimolar half-maximum inhibitory concentration (IC50) values 
for NMP (Fig.5). Affinity to BRD2 and BRD4 as a whole are 3.3 mM and 3.4 mM respectively 
and therefore very similar. 
 
 
Discussion 
 In an ovariectomized rats model, mimicking menopause, we recently showed that N-
methyl pyrrolidone (NMP) prevents bone loss and improves both mass and quality of bones 
[24]. In the present study, we examined whether NMP could reduce obesity and obesity-related 
metabolic disorders in ovariectomized rats. During menopausal transition many women gain 
weight and weight gain risks such as high blood pressure, heart diseases, and diabetes. 
Overweight and obesity in menopausal women are important public health concerns especially 
in an aging society [13]. In our study, ovariectomy induced a decrease in estradiol level which 
was accompanied by an increase in marrow fat content. NMP administration was not able to 
significantly restore estradiol level; however, fat fraction in bone marrow and abdominal fat 
was markedly decreased by the treatment compared to ovariectomized non-treated group. This 
suggests that NMP acts via an estrogen-independent mechanism.   
 Moreover, the weight gain and abdominal fat accumulation in postmenopausal women 
cause a higher risk for insulin resistance [30, 31]. Additionally, clinical data have shown that 
other cytokines, such as TNF-α, leptin and adiponectin are also involved in insulin resistance 
[32, 33]. In our study, NMP treatment reversed the effect of ovariectomy on serum TNF-α and 
leptin levels. These results are in agreement with the fact that NMP decreases body weight gain 
and that in humans, TNF-α and leptin are known to increase with body mass index [34]. 
 Another consequence of estrogen deficiency is white adipose tissue (WAT) 
accumulation [3]. Indeed, in the present study, ovariectomy induced an increase in the area and 
circumference of adipocytes compared to Sham group. NMP treatment was able to reverse the 
area and circumference alterations suggesting that NMP reduces the total fat mass probably by 
inhibiting adipocyte differentiation and maturation. This hypothesis is supported by the fact that 
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osteoblasts and adipocytes differentiate from the same progenitor and that we have already 
demonstrated that NMP favors osteoblast differentiation and bone regeneration [24, 23]. 
Different studies showed that in addition to stimulating osteoblast differentiation and bone 
formation, the suppression of adipogenesis may be of considerable significance to prevent or 
treat osteoporosis [35, 36]. In support of this notion, it has been shown that alendronate, a drug 
used to treat osteoporosis in postmenopausal women, can delay adipogenesis and enhance 
osteogenesis by reducing the expression of PPARγ, the adipogenic transcription factor, in 
human mesenchymal stem cells [37].  
Adipogenesis is initiated by the production of the key transcription factor PPARγ, which 
is responsible for inducing the expression of adipocyte-specific genes [15]. In this study, mRNA 
expression level of PPARγ in adipose tissue was 10-fold higher in ovariectomized rats 
compared to Sham group. Consistent with the effects of NMP on ovariectomy-induced fat 
accumulation and marrow adipogenesis, NMP decreased the expression of PPARγ in WAT. In 
vitro, NMP strongly inhibited the hMSCs and 3T3-L1 preadipocyte differentiation as indicated 
by reduction in Oil Red O staining and decrease of PPARγ gene expression. 
Recently, we showed that NMP acts as a low affinity bromodomain inhibitor for BRD2, 
BRD3, BRD4 and BRDT and has potential for osteoporosis treatment [24]. BRD2, a member 
of the BET family shows anti-adipogenic function in a hypomorphic mouse model and in 3T3-
L1 pre-adipocytes [38, 39]. BRD2 knock-out causes severe obesity [38]. Therefore, one would 
expect that BRD2 inhibition would induce weight gain. Our results, however, show that NMP 
despite its affinity to both bromodomains of BRD2 (Fig. 5) prevents weight gain caused by 
estrogen deficiency. This is in line with weight loss being the sole side effect of JQ1 application 
for contraception in male mice [40], where JQ1 was employed as a high affinity bromodomain 
inhibitor targeting BRD2, BRD3, BRDT and preferentially BRD4 [41]. Just recently, Jumonji 
domain-containing protein 6 (JMJD6) was found to be a nuclear protein involved in histone 
modification, transcription and RNA processing and crucial during adipogenesis [21]. JMJD6 
directs transcriptional activation of PPARγ2 during adipocyte differentiation dependent on 
BRD4 [21]. Therefore, inhibition of the scaffolding capability of BRD4 by bromodomain 
inhibitors JQ1 and NMP, as shown here, prevents transcriptional activation of PPARγ2 and in 
consequence adipogenesis. BRD2 inhibition, in this context, appears of minor importance. 
Our results show the novel action of NMP as a modulator of fat accumulation and 
adipocyte differentiation in vivo and in vitro. Epigenetic therapy with small molecules which 
act as bromodomain inhibitors such as NMP may be an effective strategy to lower adipogenic 
activity. This suggests that small molecules like NMP which regulate epigenetic alterations are 
valuable tools for treatment of various diseases and conditions. Particularly, research efforts 
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should focus on the role of small molecules which due to their bromodomain inhibitor 
properties can act as pluripotent epigenetic therapies for a wide range of diseases. 
 
Conclusion: The low affinity bromodomain inhibitor NMP inhibits the adipogenic effect of 
estrogen deficiency at the level of PPARγ expression by inhibition of BRD4.  
 
 
METHODS 
Animals and treatment 
 Female Sprague-Dawley (SD) rats (wt. 230 ± 10 g) were obtained from Charles River 
laboratories. The animals were adapted to laboratory environment for 2 weeks. In 3 independent 
experiments a total of 30 animals were used. The acclimatized rats underwent either bilateral 
laparotomy (Sham Veh, Ntotal=10) or bilateral ovariectomy (OVX, Ntotal=20). In the first two 
experiments, 3 animals per group Sham rats treated with PBS (Sham_Veh), ovariectomized rats 
treated with PBS (OVX_veh) and ovariectomized rats treated with NMP (OVX_NMP) were 
used. In the third experiment, 4 animals per group were used. In total we had 10 animals per 
group from 3 independent experiments.  
 After recovering from surgery for a week, the OVX rats were divided into 2 groups: OVX with 
vehicle (OVX Veh, Ntotal=10) and OVX with NMP (OVX NMP, 1/3 of LD50 = 
105µl/100g/week, equals an overall concentration of 10.5 mM, Ntotal=10). Treatment consisted 
of intraperitoneal injection of NMP initiated 1 week after and lasted for 15 weeks. The body 
mass of each rat was monitored weekly, and the administered dose was adjusted accordingly. 
All animal procedures were approved by the Animal Ethics Committee of the local authorities 
(Canton Zurich, 40/2012).  
 Blood sample was collected via abdominal aorta puncture immediately following 
sacrifice by CO2 asphyxiation. Then, a serum specimen was harvested after centrifugation 
(2000 rpm for 20 min). Samples were stored at −80°C until further testing and analysis. White 
adipose tissues and femurs were also removed, fixed and embedded in paraffin (Sophistolab 
AG, Muttenz, Switzerland). All samples were then stained with H&E. Femur samples were 
analyzed for bone marrow adiposity while white fat tissues were analyzed for different known 
adipocytes parameters. One part of freshly excised adipose tissue was immediately dissected, 
cut into small pieces suitable for rapid penetration by the RNAlater RNA Stabilization Reagent 
(Qiagen GmbH, Hilden, Germany), and submerged according to the manufacturer’s protocol. 
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Serological Analysis of different markers 
 Serum markers were analyzed by ELISA to monitor the NMP treatment effect on 
different metabolic markers. Serum concentration of estradiol (Takara Bio Europe, France), 
tumor necrosis factor alpha (TNFα), and leptin (Uscn Life Science, Cologne, Germany) were 
measured according to the manufacturer’s instructions.  
 
AlphaScreening assay 
 AlphaScreening assay was performed using recombinant bromodomains and 
bromodomain ligands or recombinant BET bromodomains and BET ligands from BPS 
Bioscience (San Diego, USA). The AlphaScreening signal from the assay is correlated with the 
amount of bromodomain/BET ligand binding to the bromodomain. AlphaScreening signal was 
measured using EnSpire Alpha 2390 Multilabel reader (Perkin Elmer). Binding experiments 
were performed in duplicate. AlphaScreening data were analyzed using the computer software, 
Graphpad Prism. In the absence of the compound, the AlphaScreening signal (At) in each data 
set was defined as 100% activity. In the absence of the bromodomain/BET ligand, the 
AlphaScreening signal (Ab) in each data set was defined as 0% activity. The percent activity in 
the presence of each compound was calculated according to the following equation: % activity 
= [(A − Ab) / (At − Ab)] × 100, where A = AlphaScreening signal in the presence of the 
compound, Ab = AlphaScreening signal in the absence of the bromodomain/BET Ligand, and 
At = AlphaScreening signal in the absence of the compound. The percent inhibition was 
calculated according to the following equation: % inhibition = 100 − % activity. Values of % 
activity versus a series of compound concentrations were then plotted using non-linear 
regression analysis of Sigmoidal dose–response curve generated with the equation Y = B+(T − 
B) / 1 + 10((LogEC50 − X) × Hill Slope), where Y = percent activity, B = minimum percent activity, T 
= maximum percent activity, X = logarithm of compound and Hill Slope = slope factor or Hill 
coefficient. The IC50 value was determined by the concentration causing a half-maximal 
percent activity. 
 
 
Cell culture and differentiation of hMSCs 
 Human mesenchymal stromal cells derived from bone marrow were provided 
from Ehrbar Laboratory at University Hospital Zurich.  The cells were cultured as previously 
described in [42]. For adipogenic differentiation, cells were plated at 4×103 cells/cm2 and 
cultured in α-MEM medium with 10% fetal bovine serum (FBS), 0.5 mM isobutyl-
methylxanthine (IBMX), 1 µM dexamethasone, 10 µM insulin, and 100 µM indomethacin. The 
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medium was changed every 2 days and after 14 days fat droplet formation was analyzed by Oil 
Red staining using microscopy and semiquantitative analysis at λ490 nm using a Synergy HT 
ELISA microplate reader (BioTek) 
 
 
Cell culture and differentiation of 3T3-L1 cells 
 The 3T3-L1 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA, USA) with 10% FBS at 37°C in 5% CO2. The cells were 
seeded at a density of 4×105 cells/well into a 6-well plate. At 2 days post-confluence (day 0), 
the cells were exposed to an MDI solution (induction  solution) containing 0.5 mM IBMX, 1 
μM of dexamethasone and 10μg/ml of insulin for 2 days. Following induction, cells were 
switched to a solution containing complete DMEM medium supplemented with 1µg/ml insulin 
(maintaining solution). The medium was changed every 2 days for a total of 10 days. To 
examine the effects of NMP on the differentiation of pre-adipocytes into adipocytes, the cells 
were treated with various concentrations of NMP at 2 days post confluence (day 0) and each 
time the medium was changed. The fat droplet formation was analyzed by Oil Red staining 
using microscopy and semiquantitative analysis at λ490 nm using a Synergy HT ELISA 
microplate reader (BioTek). 
 
Oil Red O staining 
 For quantification, cells were fixed with 10% neutral formalin for 1 h at room 
temperature, washed with phosphate-buffered saline (PBS) and then stained for 1 h with 0.5% 
Oil Red O in 60% isopropanol. After washing with distilled water, the stained cells were 
observed under a microscope. The stained lipid droplets were then extracted with isopropanol 
for quantification by measuring its absorbance at 490 nm. 
 
RT-PCR 
 Samples of the dissected adipose tissue (100 mg) in weight were prepared and processed 
with RNeasy Mini Kit and RNeasy Lipid Tissue Kit (both QIAGEN GmbH, Hilden, Germany) 
according to the manufacturer’s protocols. The mRNA was reverse-transcribed and resultant 
cDNA was subjected to real-time PCR with gene-specific primers using iQ SYBR Green 
Supermix and an iCycler real-time PCR machine (both from Bio-Rad, Cressier, Switzerland) 
according to the manufacturer’s instructions. All primers were purchased from Qiagen. Relative 
gene expression was analyzed using 2-∆∆Ct method as previously described [43]. 
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Histology 
 Paraffin sections of rat femurs and white adipose tissues collected for histological 
analysis were prepared and stained with hematoxylin and eosin (H&E) as formerly described 
[23]. Five sections from 5 different animals (chosen randomly) were examined for changes. 
The sections were visualized with a Leitz Dialux20 microscope and images captured using a 
Leica camera. 
 
Statistical analysis 
 All statistical analyses were performed with IBM SPSS statistics 22. Data from all 
parameters were normally distributed (Shapiro–Wilk test). Results are expressed as the mean ± 
SD and were compared by ANOVA and Student's t-test. Results were considered significantly 
different for P < 0.05. 
 
 
 
Availability of supporting data 
Additional file 1: Effect of NMP visceral adipose tissue: OVX increases visceral fat and this 
increase can be reversed by NMP treatment. 
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Figure legends: 
 
 
Figure 1 
Changes in body weight, marrow adiposity  and biomarkers of the OVX animal model: 
(A) The animal groups of the study were the following, OVX rats not treated with NMP (OVX 
Veh), OVX NMP rats treated with 105µl/100g/week of NMP and Sham animals (Sham Veh) 
not treated with NMP and not ovariectomized. Significant difference in body weight is shown 
between animal groups from week 3 to week 12 of treatment (Sham Veh vs OVX Veh ** and 
OVX Veh vs OVX NMP). (B) Representative images of mid-diaphyseal femoral marrow 
sections from different groups after 15 weeks of treatment. (C) Estradiol, TNF-α and leptin 
serum level were also compared between groups (Sham Veh vs OVX Veh * (P<0.05) and OVX 
Veh vs OVX NMP ¶ (P<0.05)). Values are mean ± SD; error bars in the figure are presented as 
SD.   
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Figure 2 
Effects of NMP treatment on histologic sections and PPARγ from WAT of ovariectomized 
rats: 
(A) Histology of white adipose tissue (WAT) with hematoxylin and eosin staining. (B) 
Characteristics of adipocytes in OVX rats analyzed using ImageJ software. (C) The effects of 
rat ovariectomy and NMP treatment on PPARγ mRNA expression. RT-PCR are presented from 
samples obtained from Sham-operated (SHAM), ovariectomized (OVX), and ovariectomized 
rats treated with NMP **P < 0.01 vs. SHAM; ¶ P < 0.01 vs. OVX. 
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Figure 3 
Influence of NMP on adipocytes differentiation from hMCS :  
(A) Human bone marrow-derived mesenchymal cells (MSCs) were induced into adipogenesis 
by differentiation medium (MDI) containing IBMX, dexamethasone, indomethacin and insulin 
as described in Methods. After 14 days, the lipid droplets were stained with Oil red O. For the 
quantitative analysis, Oil Red O staining was extracted with isopropyl alcohol and the 
absorbance at ʎ490 nm was measured. Data are presented as mean ± S.D.. (B) Representative 
micrographs showing the cell monolayers stained with Oil Red O. As seen from the staining 
and the quantification in cells treated with differentiation medium alone there is much more 
lipid accumulation than in cells treated with both differentiation medium and NMP (5 mM and 
10 mM). However, no significant difference was observed between the two different doses of 
NMP. (C) Real-time PCR analysis for PPARγ mRNA expression. The levels of PPARγ were 
normalized to the levels of PPIA, suitable reference genes during adipogenic differentiation of 
MSCs. Result is presented as ΔΔCT.*P < 0.01 MDI-treated cells vs. Control; ¶ P < 0.05 
NMP+MDI-treated cells vs. MDI-treated cells. 
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Figure 4 
Influence of NMP on 3T3-L1 adipogenic maturation:  
(A) Two-day post-confluent 3T3-L1 preadipocytes were cultured with differentiation medium 
(MDI) in the absence or presence of NMP (5 or 10 mM) for 10 days. (B) Representative 
micrographs showing the cell monolayers stained with Oil Red O. For the quantitative analysis, 
Oil Red O staining was extracted with isopropyl alcohol and the absorbance at ʎ490 nm was 
measured. Data are presented as mean ± S.D.. (C) Real-time PCR was used to quantify the 
effect of NMP on adipogenic gene expression (PPARγ). On day 8, PPARγ mRNA expression 
was analyzed by real-time PCR. Result is presented as ΔΔCT.*P < 0.01 MDI-treated cells vs. 
Control; ¶ P < 0.01 NMP+MDI-treated cells vs. MDI-treated cells. 
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Figure 5  
NMP binding to bromodomains:  
The effect of NMP on the binding of diverse recombinant BET bromodomains using the 
AlphaScreening assay. The millimolar half-maximum inhibitory concentration (IC50) of NMP 
is provided for each protein.  (A) BRD2 BD1; (B) BRD2 BD2; (C) BRD2 BD1BD2; (D) BRD4 
BD1BD2). 
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Supplemental Fig.1.  
Effect of NMP visceral adipose tissue:  
Remarkable difference is noticed in visceral adipose tissue (VAT) between (A) Sham Veh 
group (control) and (B) OVX Veh group during sacrifice. While, in (C) OVX NMP group the 
visceral adipose tissue content is similar to the control group.  
 
 
